Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
SOPHiA GENETICS (Nasdaq: SOPH) has announced significant adoption of its MSK-ACCESS® and MSK-IMPACT® cancer testing applications powered by SOPHiA DDM™. Thirty-seven prominent institutions globally have adopted these recently launched Liquid Biopsy and Solid Tumor applications, with thirty-four specifically choosing MSK-ACCESS® within ten months of its launch.
Notable adopters include Heidelberg University Hospital, Hospital del Mar, Jewish General Hospital, and the Jiménez Díaz Foundation. The decentralized deployment enables institutions to conduct world-renowned testing in-house, offering less-invasive options for patients with potentially lower costs and faster turnaround times.
This milestone follows SOPHiA GENETICS' 2023 partnership with Memorial Sloan Kettering Cancer Center and their October 2024 agreement with AstraZeneca to accelerate MSK-ACCESS® deployment globally. The company launched MSK-IMPACT® for Solid Tumor testing in November 2024.
SOPHiA GENETICS (Nasdaq: SOPH) ha annunciato una significativa adozione delle sue applicazioni per il testing del cancro MSK-ACCESS® e MSK-IMPACT® alimentate da SOPHiA DDM™. Trentasette istituzioni di rilievo a livello globale hanno adottato queste applicazioni per Biopsia Liquida e Tumori Solidi, con trentaquattro che hanno scelto specificamente MSK-ACCESS® entro dieci mesi dal suo lancio.
Tra i noti adottanti ci sono l'Ospedale Universitario di Heidelberg, l'Ospedale del Mar, l'Ospedale Generale Ebraico e la Fondazione Jiménez Díaz. Il dispiegamento decentralizzato consente alle istituzioni di condurre test di fama mondiale internamente, offrendo opzioni meno invasive per i pazienti con costi potenzialmente inferiori e tempi di risposta più rapidi.
Questa pietra miliare segue la partnership del 2023 di SOPHiA GENETICS con il Memorial Sloan Kettering Cancer Center e il loro accordo di ottobre 2024 con AstraZeneca per accelerare il dispiegamento globale di MSK-ACCESS®. L'azienda ha lanciato MSK-IMPACT® per il testing dei Tumori Solidi nel novembre 2024.
SOPHiA GENETICS (Nasdaq: SOPH) ha anunciado una adopción significativa de sus aplicaciones de pruebas de cáncer MSK-ACCESS® y MSK-IMPACT® impulsadas por SOPHiA DDM™. Treinta y siete instituciones prominentes a nivel mundial han adoptado estas aplicaciones recientemente lanzadas para Biopsia Líquida y Tumores Sólidos, con treinta y cuatro eligiendo específicamente MSK-ACCESS® en los diez meses siguientes a su lanzamiento.
Entre los adoptantes notables se encuentran el Hospital Universitario de Heidelberg, el Hospital del Mar, el Hospital General Judío y la Fundación Jiménez Díaz. El despliegue descentralizado permite a las instituciones realizar pruebas de renombre mundial internamente, ofreciendo opciones menos invasivas para los pacientes con costos potencialmente más bajos y tiempos de respuesta más rápidos.
Este hito sigue a la asociación de SOPHiA GENETICS en 2023 con el Memorial Sloan Kettering Cancer Center y su acuerdo de octubre de 2024 con AstraZeneca para acelerar el despliegue global de MSK-ACCESS®. La compañía lanzó MSK-IMPACT® para pruebas de Tumores Sólidos en noviembre de 2024.
SOPHiA GENETICS (Nasdaq: SOPH)는 SOPHiA DDM™을 기반으로 한 MSK-ACCESS® 및 MSK-IMPACT® 암 검사 애플리케이션의 중요한 채택을 발표했습니다. 전 세계 37개의 저명한 기관이 최근 출시된 액체 생검 및 고형 종양 애플리케이션을 채택했으며, 그 중 34개 기관이 출시 10개월 이내에 MSK-ACCESS®를 선택했습니다.
주요 채택 기관으로는 하이델베르크 대학교 병원, 마르 병원, 유대인 일반 병원, 히메네스 디아즈 재단이 있습니다. 분산형 배포 방식은 기관이 세계적으로 유명한 검사를 내부에서 수행할 수 있게 하여, 환자에게 덜 침습적인 옵션을 제공하고 잠재적으로 낮은 비용과 더 빠른 처리 시간을 제공합니다.
이 이정표는 SOPHiA GENETICS가 2023년에 Memorial Sloan Kettering Cancer Center와 파트너십을 체결한 후, 2024년 10월에 AstraZeneca와 MSK-ACCESS®의 전 세계 배포를 가속화하기 위한 계약을 체결한 것입니다. 이 회사는 2024년 11월에 고형 종양 검사를 위한 MSK-IMPACT®를 출시했습니다.
SOPHiA GENETICS (Nasdaq: SOPH) a annoncé une adoption significative de ses applications de tests de cancer MSK-ACCESS® et MSK-IMPACT® alimentées par SOPHiA DDM™. Trente-sept institutions de premier plan dans le monde entier ont adopté ces applications récemment lancées pour biopsie liquide et tumeurs solides, dont trente-quatre ont spécifiquement choisi MSK-ACCESS® dans les dix mois suivant son lancement.
Parmi les adoptants notables figurent l'Hôpital Universitaire de Heidelberg, l'Hôpital del Mar, l'Hôpital Général Juif et la Fondation Jiménez Díaz. Le déploiement décentralisé permet aux institutions de réaliser des tests de renommée mondiale en interne, offrant des options moins invasives pour les patients, avec des coûts potentiellement plus bas et des délais de réponse plus rapides.
Cette étape importante fait suite au partenariat de SOPHiA GENETICS en 2023 avec le Memorial Sloan Kettering Cancer Center et à leur accord d'octobre 2024 avec AstraZeneca pour accélérer le déploiement mondial de MSK-ACCESS®. L'entreprise a lancé MSK-IMPACT® pour les tests de tumeurs solides en novembre 2024.
SOPHiA GENETICS (Nasdaq: SOPH) hat eine bedeutende Akzeptanz seiner MSK-ACCESS®- und MSK-IMPACT®-Anwendungen zur Krebsdiagnose, die von SOPHiA DDM™ unterstützt werden, bekannt gegeben. Siebenunddreißig angesehene Institutionen weltweit haben diese kürzlich eingeführten Anwendungen für Flüssigbiopsien und feste Tumoren übernommen, wobei vierunddreißig speziell innerhalb von zehn Monaten nach der Einführung MSK-ACCESS® gewählt haben.
Zu den bemerkenswerten Anwendern gehören das Universitätsklinikum Heidelberg, das Hospital del Mar, das Jüdische Allgemeine Krankenhaus und die Jiménez Díaz Stiftung. Der dezentrale Einsatz ermöglicht es Institutionen, weltweit renommierte Tests intern durchzuführen, wodurch weniger invasive Optionen für Patienten sowie potenziell niedrigere Kosten und schnellere Bearbeitungszeiten angeboten werden.
Dieser Meilenstein folgt auf die Partnerschaft von SOPHiA GENETICS im Jahr 2023 mit dem Memorial Sloan Kettering Cancer Center und deren Vereinbarung im Oktober 2024 mit AstraZeneca zur Beschleunigung des globalen Einsatzes von MSK-ACCESS®. Das Unternehmen startete MSK-IMPACT® für die Testung von soliden Tumoren im November 2024.
- Rapid adoption with 37 prominent institutions implementing the technology
- 34 institutions specifically adopted MSK-ACCESS® within 10 months of launch
- Strategic partnership with AstraZeneca to accelerate global deployment
- Decentralized testing enables lower costs and faster turnaround times
- None.
Insights
The rapid adoption of SOPHiA GENETICS' MSK testing applications represents a significant strategic advancement in the $7.8 billion global liquid biopsy market. The securing of 34 institutional partners for MSK-ACCESS® within just 10 months demonstrates exceptional market validation and positions SOPHiA GENETICS as a pivotal player in the precision oncology space.
The partnership ecosystem, particularly with Memorial Sloan Kettering Cancer Center and AstraZeneca, creates a powerful competitive moat. This collaboration model enables SOPHiA GENETICS to leverage MSK's renowned cancer testing capabilities while utilizing AstraZeneca's global commercial infrastructure for accelerated market penetration. The decentralized testing approach offers a compelling value proposition: institutions can maintain control over patient data while reducing costs and turnaround times, creating a sustainable competitive advantage.
The geographic diversity of adopting institutions - spanning Europe, North America, and Asia - suggests strong product-market fit across different healthcare systems. This global footprint is particularly valuable for building a comprehensive real-world data repository, which becomes increasingly valuable with each new institution added to the network. The expanding data ecosystem creates a virtuous cycle: more institutional adoption leads to richer datasets, which in turn enhances the AI capabilities of the SOPHiA DDM™ platform, attracting more users.
The strategic focus on both liquid biopsy (MSK-ACCESS®) and solid tumor testing (MSK-IMPACT®) positions SOPHiA GENETICS to capture a larger share of the oncology testing market. This dual approach allows healthcare providers to offer comprehensive cancer testing solutions, potentially increasing per-institution revenue through broader test utilization.
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing
Professor Umberto Malapelle, Chair of the Predictive Molecular Pathology Laboratory at the Department of Public Health of the University Federico II of
"When I learned SOPHiA GENETICS was offering applications from MSK on the SOPHiA DDM™ platform, I was really interested in the evaluation of the performance of this test, in particular because I see SOPHiA GENETICS as true collaborators to help pave the way for the future of cancer research," said Professor Malapelle.
"Bringing best-in-class technology to global organizations is crucial to help advance better health care for all. We are proud to work with trailblazers like Professor Malapelle, who are utilizing our technology and the collective power of our network to make strides in the next wave of cancer care," said Ross Muken, President, SOPHiA GENETICS.
Of the thirty-seven institutions adopting MSK solutions, thirty-four have signed on to adopt MSK-ACCESS® powered with SOPHiA DDM™, just ten months after the Liquid Biopsy application's launch. The decentralized deployment of MSK-ACCESS® has enabled hospitals and labs across the globe to launch world-renowned Liquid Biopsy testing from within the walls of their own institution, providing patients with a less-invasive option for genomic testing. In many cases, this decentralized testing also results in lower costs and faster turnaround times, while also enabling institutions to retain control of their patients' data for research or other purposes.
Internationally recognized organizations adopting the application include: Heidelberg University Hospital in
The complementary solid tumor application, MSK-IMPACT® powered with SOPHiA DDM™, has also attracted significant interest from leading organizations across the globe, including: the Jiménez Díaz Foundation University Hospital in
Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS partnered in 2023 with a vision to use the sophisticated technology of the SOPHiA DDM™ Platform to bring MSK's state-of-the-art cancer testing capabilities to precision medicine institutions worldwide. The two leaders launched the Liquid Biopsy test MSK-ACCESS® powered with SOPHiA DDM™ in April 2024. In October 2024, SOPHiA GENETICS announced a definitive partnership agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™, aiming to increase the availability of this innovative Liquid Biopsy solution worldwide. In November 2024, SOPHiA GENETICS announced the launch of the complementary Solid Tumor test, MSK-IMPACT® powered with SOPHiA DDM™. These collaborations have the potential to transform cancer research as they enable healthcare providers to draw from a continuously evolving base of real-world data and gain insights from diverse populations while using best-in-class technology.
Join us on Tuesday, February 25, 2025, at 11:00 a.m. (11:00) EDT / 5:00 p.m. (17:00) CET for the Precision Oncology Showcase, a virtual webinar which will spotlight the transformative potential of decentralized, AI-driven technologies for the advancement of cancer care.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/leading-healthcare-institutions-adopt-msk-access-for-liquid-biopsy-testing-302383208.html
SOURCE SOPHiA GENETICS
FAQ
How many institutions have adopted SOPHiA GENETICS' MSK-ACCESS® testing platform as of February 2025?
What are the benefits of SOPHiA GENETICS' decentralized testing approach for hospitals?
When did SOPHiA GENETICS (SOPH) partner with AstraZeneca for MSK-ACCESS® deployment?
Which major healthcare institutions have adopted SOPHiA GENETICS' MSK testing solutions?
When did SOPHiA GENETICS launch the MSK-IMPACT® Solid Tumor testing solution?
